top of page
Curriculum Vitae

Dr. Yossi Lomnicky

Year of birth: 1957
Marital status: Married+3 children
Army service: 1980-2001
Address: Hateena 25, Givat Shmuel, Israel
Tel: 972-3-5326388
Cell: 972-50-8800188
Fax: 972-3-5326375

Education

  • 1975-1979 :B.Pharm. Hebrew University, Jerusalem, Israel.  (School of Pharmacy)

  • 1983- 1988 : Computer sciences, Bar-Ilan University, Ramat-Gan, Israel

  • 1989- 1993 : M. Pharm. with distinction, Hebrew University, Jerusalem, Israel. (School of Pharmacy)

  • Thesis: ‘Development of Novel Allometric Equations Describing The Pharmacokinetics of Pentobarbital, Thiopental and Valproic Acid in Several species and Humans: Prof. Meir Bialer . Hebrew University, Jerusalem, Israel.

  • 1993-1998: Ph.D., with distinction, Hebrew University, Jerusalem, Israel. (School of Pharmacy)

  • Thesis: The Effect of Mode of administration of Hypolipidemic Drugs and Establishment of a Pharmacodynamic Rationale for the Development of an Oral Controlled Release Formulation for These Drugs.

  • 2000-2001: “Business Management for Directors”, the Israeli Center for Management, Tel Aviv.

  • 2005-2005: “General and Economical Management of Health Systems Organizations and Hospitals”, the Israeli Center for Management, Tel Aviv.

Positions Held

  • Israel Defense Forces: 1980- 2000:  

  •  Last position - 1994-2000: Chief Pharmacist and Head of Medical Equipment Branch at the Surgeon General HQ.

  •  2001- 2022: Chief Pharmacist and Director Pharmacology and Pharmaceutics array at the headquarter of MACABBI Health Care Services (HMO) – The second largest HMO in Israel.

​Some of my initiatives I have implemented in the HMO:

1.        Planning and Establishing monitoring and a control processes in the HMO -  Maccabi,        

whose role is cost containment over the uses of the drugs.

2.       Establishment regional pharmacists array who are responsible for quality and financial control of the usage of medications prescribed by Maccabi's physicians in their region.

3.       Establishment of a unique and primary service in the world of clinical pharmacists that advice the physicians about drugs treatments in order to optimize drug treatments.

4.       Establishment of a national drug pre-authorization center for the purpose of assuring the optimal use of expensive drugs.

5.       Establishment of a national exceptions committee that approves innovative medical treatments according to the best of the professional clinical literature while balancing with economic and quality parameters.

6.       Establishment of a computational system for implementing an optimal drug treatment policy through at Maccabi's.

7. Reducing the expenditures and waste of very expensive medication such as oncology and Heamato-oncology drugs by sharing ampules.

 

  • 2006 – 2014 : Adviser, Medication Policy, Ministry of Defense .

List Of Publications

Thesis:

 

  1. Lomnicky,Y. Thesis: ‘ Development of Novel Allometric Equations Describing the Pharmacokinetics of Pentobarbital, Thiopental and Valproic Acid in Several species and Humans.

  2. Lomnicky,Y. Thesis: The Effect of Mode of administration of Hypolipidemic Drugs and Establishment of A Pharmacodynamic Rationale for the Development of an Oral Controlled Release Formulations for These Drugs.

 

Full Papers:

 

3. Lomnicky Y. Are Humans Above all Animals?? MIRSHAM YSRAELI, 1994 (14-19).

4. Hoffman A., Lomnicky Y., Luria M.H., Haimov T. and Friedman M., Hypolipidemic 

    Activity following continuous gastrointestinal administration of  Low Dose

    Niacin in

    Rats. Pharm. Res. 12:5403, 1995.

5. Hoffman A., Lomnicky Y., Luria M.H., Haimov T. and Friedman M., Continuous

    Gastrointestinal Infusion of Bezafibrate (Alone and With Combination) With      Niacin Improves the Hypolipidemic Activity in Rats.   Pharm. Res. 13:5415,      1996.

6. Lomnicky Y, Haimov T, Luria MH, Hoffman A. Pharmacodynamic effects of

    Bezafibrate and niacin combination: improved mode of administration. J.         Pharm. Sci. 2000 Aug;89(8):1046-53.

7. Hoffman A., Lomnicky Y., Luria M.H., Gilhar D and Friedman M., Improved Lipid

    Lowering Activity of Bezafibrate Following Continuous Gastrointestinal

    Administration: Pharmacodynamic Rational for Sustained Release  

    Preparation of the Drug. Pharm. Res. 1999 Jul;16(7): 1093-1097.

8.  Lomnicky Y., Luria M.H. , Friedman M. and Hoffman A.,  The Effect of Mode of

     Administration on the Hypolipidemic Activity of Niacin: Continuous Gastrointestinal Administration of Low-Dose Niacin Improves Lipid-Lowering      Efficacy in Experimentally Induced Hyperlipidemic Rats. J. Pharm. Pharmacol. 1998 Nov;50(11):         

     1233-1239.

9.  Rubnov S., Amisar S., Lomnicky Y., and Schneider H. Influence of trimedoxim bromide on

     degradation of  Benactizine in Acidic   Injectable Solutions. Eur. J. Pharm. Sci. 1999 Feb;7(3):  

      191-196

10. Hoffman A. and Lomnicky Y. Pharmacodynamic rationale for optimizing drug

    delivery. Brit. J. Clin. Pharm. Ther. 1999, p.13.

11. Lomnicky Y., Haimov T., Luria M.H., Friedman M. and Hoffman A.The combined

    Lipid-lowering effect of Bezafibrate and niacin: Implication of the mode of

    administration. Brit. J. Clin. Pharm. Ther. 1999, p.61.

12. Halkin H., Dushenat M., Silverman B., Shalev V., Lobstein R., Lomnicky Y., Friedman N.  

      Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann

      Pharmacother. 2007 Jan;41(1) 29-34.

13. Kahan NR., Friedman NL., Lomnicky Y., Hemo B., Heymann AD., Shapiro M., Kokia E.

      Physician specialty and adherence to guidelines for the treatment of unsubstantiated

      uncomplicated urinary tract infection among women. Pharmacoepidemiol Drugs Saf.

      2005May;14(5):357-61.

14. I. Katzir, R. Loebstein J. vesterman Landes, H. Halkin, Y. lomnicky. Database I. Katzir, R. Loebstein J. vesterman Landes, H. Halkin, Y. lomnicky. Database assesment of the effectiveness of brand versus generic rosiglitazone in patients with type 2 diabetes melitus. Med Sci Monit. 2008 Jun;14(6):CR323-326

15. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Clin Ther. 2011 Apr;33(4):456-64. doi: 10.1016/j.clinthera.2011.04.011.

16. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R. Breast Cancer Res Treat. 2011 Jan;125(2):505-10. doi: 10.1007/s10549-010-1008-7. Epub 2010 Jul 1.

17. Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R. Breast Cancer Res Treat. 2011 Jan;125(2):505-10. Epub 2010 Jul 1.  Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.

18. Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H. J Clin Pharmacol. 2011 Feb;51(2):173-80. Epub 2010 May  Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

19.  Aviner S, Berkovitch M, Dalkian H, Braunstein R, Lomnicky Y, Schlesinger M.Pediatrics. 2010 Feb;125(2):e318-23. Epub 2010 Jan 25.  Use of a homeopathic preparation for "infantile colic" and an apparent life-threatening event.

20. Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Clin Endocrinol (Oxf). 2011 Dec 23. doi: 10.1111/j.1365-2265.2011.04321.x. [Epub ahead of print] Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins.

21. Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R.  Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.

22. Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H. J Clin Pharmacol. 2011 Feb;51(2):173-80. Epub 2010 May 19. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

23. Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Clin Ther.    2011 Apr;33(4):456-64.  Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.

24. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Siegelmann-Danieli N, Katzir I, Landes JV, Segal Y, Bachar R, Rabinovich HR, Bialik M, Azuri J, Porath A, Lomnicky Y. Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491-2.

25. Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Katz G, Moisseiev E, Goldenberg D, Moisseiev J, Lomnicky Y, Abend Y, Treister G, Levkovitch-Verbin H. Eur J Ophthalmol. 2017 Mar 10;27(2):210-214. doi: 10.5301/ejo.5000838. Epub 2016 Jul 18.

26. Trends in annual drug expenditure - a 16 year perspective of a public healthcare maintenance organization. Lomnicky Y, Kurnik D, Loebstein R, Katzir I, Vesterman-Landes J, Siegelmann-Danieli N. Isr J Health Policy Res. 2016 Sep 15;5:37. doi: 10.1186/s13584-016-0096-1. eCollection 2016.

27. A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting.  Siegelmann-Danieli N, Farkash A, Katzir I, Vesterman Landes J, Rotem Rabinovich H, Lomnicky Y, Carmeli B, Parush-Shear-Yashuv N. PLoS One. 2016 May 4;11(5):e0154689. doi: 10.1371/journal.pone.0154689. eCollection 2016.

28. Database evaluation of the association between serum magnesium levels and the risk of atrial fibrillation in the community. Markovits N, Kurnik D, Halkin H, Margalit R, Bialik M, Lomnicky Y, Loebstein R. Int J Cardiol. 2016 Feb 15;205:142-146. doi: 10.1016/j.ijcard.2015.12.014. Epub 2015 Dec 15.

29. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch? Moisseiev E, Katz G, Moisseiev J, Loewenstein A, Goldstein M, Lomnicky Y, Abend Y, Treister G, Goldenberg D, Levkovitch-Verbin H.

30. The association of proton pump inhibitors and hypomagnesemia in the community setting. Markovits N, Loebstein R, Halkin H, Bialik M, Landes-Westerman J, Lomnicky J, Kurnik D.J Clin Pharmacol. 2014 Aug;54(8):889-95. doi: 10.1002/jcph.316. Epub 2014 May 6.

31. [The implementation of innovative medical technologies: biological pharmaceuticals for the treatment of psoriasis--a case study].Tal O, Lomnicky Y.Harefuah. 2012 Jun;151(6):368-71, 376. Hebrew.

32. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins.Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y, Halkin H, Loebstein R.Clin Endocrinol (Oxf). 2012 Jul;77(1):36-41. doi: 10.1111/j.1365-2265.2011.04321.x.

bottom of page